valsartan has been researched along with cilnidipine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Shigemasa, M; Takami, T | 1 |
| Ishikawa, H; Katayama, K; Koyabu, S; Murata, T; Nakano, T; Nomura, S | 1 |
| Aritomi, S; Koganei, H; Konda, T; Mitsui, A; Nitta, K; Ogawa, T; Wagatsuma, H | 1 |
| Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T | 2 |
| Aritomi, S; Jin, D; Miyazaki, M; Niinuma, K; Takai, S | 1 |
| Harada, E; Hattori, T; Matsuura, N; Murohara, T; Nagasawa, K; Nagata, K; Niinuma, K; Takahashi, K; Takatsu, M; Watanabe, S | 1 |
| Jang, K; Lee, H; Lee, J; Lim, KS; Shin, D; Yu, KS | 1 |
| Fujii, M; Ichikawa, M; Imagawa, M; Ishizuka, T; Kaeriyama, S; Konoshita, T; Makino, Y; Nakamura, H; Nakaya, T; Sato, S; Suzuki, J; Urabe, M; Wakahara, S; Yamada, M; Yamamoto, K; Zenimaru, Y | 1 |
| Fujiwara, T; Kanegae, H; Kario, K; Tomitani, N | 1 |
| Kario, K; Kurose, Y; Matsuda, S; Nagahama, S; Sugii, H; Suzuki, N; Teshima, T; Wakabayashi, M | 1 |
| Kario, K; Kurose, Y; Matsuda, S; Nagahama, S; Sugii, H; Suzuki, N; Teshima, T | 2 |
| Fujiwara, T; Hoshide, S; Kanegae, H; Kario, K; Tomitani, N | 1 |
5 trial(s) available for valsartan and cilnidipine
| Article | Year |
|---|---|
Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ankle; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brachial Artery; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Male; Nifedipine; Pulsatile Flow; Tetrazoles; Thiazepines; Treatment Outcome; Valine; Valsartan | 2003 |
Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.
Topics: Adult; Cross-Over Studies; Dihydropyridines; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Healthy Volunteers; Humans; Male; Tetrazoles; Valine; Valsartan; Young Adult | 2014 |
Comparative effects of valsartan plus either cilnidipine or hydrochlorothiazide on home morning blood pressure surge evaluated by information and communication technology-based nocturnal home blood pressure monitoring.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Blood Pressure Monitors; Dihydropyridines; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Medical Informatics; Middle Aged; Outcome Assessment, Health Care; Valsartan | 2018 |
Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Dihydropyridines; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2021 |
9 other study(ies) available for valsartan and cilnidipine
| Article | Year |
|---|---|
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Glomerulonephritis; Hypertension; Kidney; Kidney Diseases; Male; Organ Size; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Effects of an N-type calcium antagonist on angiotensin II-renin feedback.
Topics: Amlodipine; Angiotensin II; Animals; Calcium Channel Blockers; Calcium Channels, N-Type; Dihydropyridines; Dose-Response Relationship, Drug; Male; Models, Biological; Rats; Renin; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2011 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dihydropyridines; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Glucagon; Glucose Transporter Type 1; Glycated Hemoglobin; Glycogen; Hypertension; Kidney; Male; Norepinephrine; Proteinuria; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats.
Topics: Aldehydes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Carotid Arteries; Cysteine Proteinase Inhibitors; Dihydropyridines; Heart; Immunohistochemistry; Male; Muscle Relaxation; Muscle, Smooth, Vascular; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type III; Organ Size; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Real-Time Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan; Vascular Diseases | 2013 |
Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Dihydropyridines; Drug Evaluation, Preclinical; Drug Therapy, Combination; Heart; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Oxidative Stress; Rats, Inbred Dahl; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Valsartan | 2016 |
A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension: Real-world JSH 2014 and 2019 implementations.
Topics: Aged; Antihypertensive Agents; Blood Pressure Determination; Dihydropyridines; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Japan; Male; Product Surveillance, Postmarketing; Valsartan | 2020 |
Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE-Combi survey.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Dihydropyridines; Humans; Hypertension; Tetrazoles; Valsartan | 2020 |
Single-pill combination of cilnidipine, an l-/n-type calcium channel blocker, and valsartan reduces the day-by-day variability of morning home systolic blood pressure in patients with treated hypertension: A sub-analysis of the HOPE-combi survey.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Dihydropyridines; Humans; Hypertension; Tetrazoles; Valsartan | 2021 |